Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Evaluation of systemic exposure of nanoparticle suspensions subcutaneously administered to mice regarding stabilization, volume, location, concentration and size.

Sigfridsson K, Palmer M.

Drug Dev Ind Pharm. 2014 Oct;40(10):1318-24. doi: 10.3109/03639045.2013.817418. Epub 2013 Jul 23.

PMID:
23879245
3.

Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability.

Yang H, Teng F, Wang P, Tian B, Lin X, Hu X, Zhang L, Zhang K, Zhang Y, Tang X.

Int J Pharm. 2014 Dec 30;477(1-2):88-95. doi: 10.1016/j.ijpharm.2014.10.025. Epub 2014 Oct 14.

PMID:
25455766
4.

Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth.

Ghosh I, Bose S, Vippagunta R, Harmon F.

Int J Pharm. 2011 May 16;409(1-2):260-8. doi: 10.1016/j.ijpharm.2011.02.051. Epub 2011 Mar 1.

PMID:
21371540
5.

Optimization of formulation and process parameters for the production of nanosuspension by wet media milling technique: effect of Vitamin E TPGS and nanocrystal particle size on oral absorption.

Ghosh I, Schenck D, Bose S, Ruegger C.

Eur J Pharm Sci. 2012 Nov 20;47(4):718-28. doi: 10.1016/j.ejps.2012.08.011. Epub 2012 Aug 24.

PMID:
22940548
6.

Orally administered nanocurcumin to attenuate morphine tolerance: comparison between negatively charged PLGA and partially and fully PEGylated nanoparticles.

Shen H, Hu X, Szymusiak M, Wang ZJ, Liu Y.

Mol Pharm. 2013 Dec 2;10(12):4546-51. doi: 10.1021/mp400358z. Epub 2013 Nov 19.

7.

Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base.

Hecq J, Deleers M, Fanara D, Vranckx H, Boulanger P, Le Lamer S, Amighi K.

Eur J Pharm Biopharm. 2006 Nov;64(3):360-8. Epub 2006 Jul 18.

PMID:
16846725
8.

Study of effect of variables on particle size of telmisartan nanosuspensions using box-Behnken design.

Rao MR, Bajaj A.

Drug Res (Stuttg). 2014 Dec;64(12):663-7. doi: 10.1055/s-0034-1368701. Epub 2014 Feb 18.

PMID:
24549965
9.
10.

Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer.

Gao Y, Li Z, Sun M, Li H, Guo C, Cui J, Li A, Cao F, Xi Y, Lou H, Zhai G.

Drug Dev Ind Pharm. 2010 Oct;36(10):1225-34. doi: 10.3109/03639041003695139.

PMID:
20545506
11.

Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies.

Parveen R, Ahmad FJ, Iqbal Z, Samim M, Ahmad S.

Drug Dev Ind Pharm. 2014 Sep;40(9):1206-12. doi: 10.3109/03639045.2013.810636. Epub 2013 Jul 4.

PMID:
23826860
12.

In vitro-in vivo evaluation of nanosuspension release from subcutaneously implantable osmotic pumps.

Hill A, Geissler S, Meyring M, Hecht S, Weigandt M, Mäder K.

Int J Pharm. 2013 Jul 15;451(1-2):57-66. doi: 10.1016/j.ijpharm.2013.04.060. Epub 2013 Apr 26.

PMID:
23628403
13.

Preparation of griseofulvin nanoparticle suspension by high-pressure homogenization and preservation of the suspension with saccharides and sugar alcohols.

Kamiya S, Kurita T, Miyagishima A, Arakawa M.

Drug Dev Ind Pharm. 2009 Aug;35(8):1022-8. doi: 10.1080/03639040802698786.

PMID:
19466885
14.

Food proteins as novel nanosuspension stabilizers for poorly water-soluble drugs.

He W, Lu Y, Qi J, Chen L, Hu F, Wu W.

Int J Pharm. 2013 Jan 30;441(1-2):269-78. doi: 10.1016/j.ijpharm.2012.11.033. Epub 2012 Nov 27.

PMID:
23194889
15.

Improvement of pulmonary absorption of cyclopeptide FK224 in rats by co-formulating with beta-cyclodextrin.

Nakate T, Yoshida H, Ohike A, Tokunaga Y, Ibuki R, Kawashima Y.

Eur J Pharm Biopharm. 2003 Mar;55(2):147-54.

PMID:
12637090
16.

Role of lipid-based excipients and their composition on the bioavailability of antiretroviral self-emulsifying formulations.

Chudasama A, Patel V, Nivsarkar M, Vasu K, Shishoo C.

Drug Deliv. 2015;22(4):531-40. doi: 10.3109/10717544.2014.891270. Epub 2014 Mar 7.

PMID:
24601856
17.

Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics.

Kumar VV, Chandrasekar D, Ramakrishna S, Kishan V, Rao YM, Diwan PV.

Int J Pharm. 2007 Apr 20;335(1-2):167-75. Epub 2006 Nov 3.

PMID:
17161566
18.

Understanding a relaxation behavior in a nanoparticle suspension for drug delivery applications.

Deng Z, Xu S, Li S.

Int J Pharm. 2008 Mar 3;351(1-2):236-43. Epub 2007 Oct 10.

PMID:
18093763
19.

Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan.

Rajpoot P, Bali V, Pathak K.

Int J Pharm. 2012 Apr 15;426(1-2):219-30. doi: 10.1016/j.ijpharm.2012.01.027. Epub 2012 Jan 24.

PMID:
22301424
20.

Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development.

Sigfridsson K, Lundqvist AJ, Strimfors M.

Drug Dev Ind Pharm. 2009 Dec;35(12):1479-86. doi: 10.3109/03639040903025855.

PMID:
19929207
Items per page

Supplemental Content

Write to the Help Desk